"We don't just list assets — we identify and introduce you to the emerging researchers, find grants and projects, and geographic pockets your competitors haven't found yet."
Built by someone who has sat on both sides of the table
​
OniX Hub was founded by Martin Duenas with a simple observation: the most valuable BD intelligence — the emerging researchers, the just-funded grants, the global non-NIH ecosystems — was systematically invisible to most pharma teams and inaccessible to most academic institutions.
With leadership experience spanning pharmaceutical partnerships, research administration, healthcare innovation, and global scientific collaboration across 20+ countries, OniX bridges the gap that generic databases and consultants can't.
We don't just list assets. We tell you who is doing the most interesting work, where it's funded, what modality they're pursuing, and how to reach them — globally, in rare disease and beyond.
-
20+ countries of direct research ecosystem experience
-
Leadership in pharma, biotech, and academic partnerships
-
Deep rare disease network and more
-
OniX OnPoint newsletter: weekly intelligence since 2023
-
PIVOT series: funding strategy for institutions in crisis​
OniX aggregates the Research Ecosystem
All Ideas have an impact
OniX accepts ideas from a wide spectrum of research, including: Health Sciences, Biotechnology, Medical Devices, Agriculture, Energy, Space, Transportation, Climate Change, Food and Nutrition, Farming, Fisheries, Social Sciences, Public Health, Artificial Intelligence, Software/Hardware, and others.
​
OniX harnesses the industry's most comprehensive biomedical research database, aggregating intelligence on over 1 million curated therapeutic assets and ideas. Our platform continuously tracks 160 million scientific publications, monitors 100,000+ startups across more than 50 countries, and maintains live data from 10,000+ biotech and startup pipelines. This vast repository includes extensive patent databases, clinical trial information, and real-time industry news, all enriched weekly with 5,000+ newly identified assets.
Our global network encompasses 5,000+ universities and other research organazitations and includes proprietary tracking of stealth companies and emerging technologies. By transforming this unparalleled data collection into actionable intelligence through our AI-powered analytics, OniX provides biotech innovators with the strategic insights traditionally available only to pharmaceutical giants with extensive competitive intelligence resources.
Our Technology
OniX utilizes a sophisticated AI ecosystem that combines advanced machine learning, natural language processing, and cognitive reasoning frameworks to revolutionize the discovery of novel partners, unexplored drug targets, and alternative applications for existing therapeutic candidates. Our platform orchestrates a proprietary integration of both public and private global datasets, creating an intuitive discovery hub specifically engineered for the research community.
Key Technological Features:
-
AI-Powered Analytics: Our proprietary AI algorithms process complex biomedical data relationships to identify non-obvious connections between diseases, targets, and compounds that traditional methods may overlook.
-
Advanced Machine Learning: OniX deploys state-of-the-art deep learning models trained on comprehensive biomedical datasets to predict promising drug-target interactions with remarkable precision and significantly reduced false positives.
-
Natural Language Processing (NLP): Our sophisticated NLP engines continuously extract and synthesize insights from scientific literature, clinical trial data, and regulatory documents to maintain an up-to-date knowledge repository that enhances decision-making.
-
Cognitive Reasoning Systems: OniX leverages cognitive computing to simulate expert reasoning processes, generating hypotheses and strategic recommendations based on partial information – similar to how experienced researchers approach complex problems.
-
​
The OniX Team
Founder/CEO
+25 years of experience in academia and private foundations including Columbia University College of Physicians & Surgeons, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, Hospital for Special Surgery, NYU School of Medicine, JDRF (previously Juvenile Diabetes Research Foundation), the Patient-Centered Outcomes Research Institute (PCORI) and Leidos.
-
OniX Empire Fund - Founder/CEO
-
The Lay Empowered - Founder
Previously:
-
OnPAR - Founder
-
Leidos Life Sciences - Director
-
Patient-Centered Outcomes Research Institute (PCORI) - Founder/Director
-
JDRF - COO of Research Department
-
New York University School of Medicine - Director
-
Hospital for Special Surgery - Associate Director
-
Memorial Sloan Kettering Cancer Center - Manager
-
Weil Cornell Medical College - Faculty
-
Columbia University Vagelos College of Physicians and Surgeons, Research Associate
Hadi Makki
Chief Technology Officer
Result-minded executive focused on increasing the value of the organization through rigorous strategic planning, business process engineering and effective cost management. Excels in fostering growth in business through meticulous profit & loss management, forming strategic alliances and tactical leadership. Exceptional communication and interpersonal skills, highly effective across all organizational levels.
Career Highlights
-
Transformed and set new standards for the use of Information Technology in the largest and most influential health department in the country (New York City)
-
Created and held key senior executive positions in both public and private sectors and drove business growth through strategic thinking, rigorous planning and execution, innovation and change